Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GVK Bio Says It Found No Link Between Wyeth Prevnar Vaccine And Child Death; Inspectors Did Not Check Documentation

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - GVK Biosciences, the clinical research organization responsible for site monitoring for Wyeth's Prevnar vaccine trial in India has said it found no linkage between the administered vaccine and the death of a child, who died during the course of the clinical trials at Bangalore's St. John's Hospital's National Academy of Health Sciences

You may also be interested in...



Cleared By India's Drug Controller, GVK Bio Expects To Complete Phase III Trials On Wyeth’s Prevnar 13 By Year End

MUMBAI - GVK Biosciences, the clinical research organization undertaking Phase III clinical trials for Wyeth's advanced version of Prevnar vaccine said it hopes to complete the studies in 12 to 13 centers by the end of the year. Wyeth is testing the vaccine in India along with many other countries to examine the new product that will fight 13 strains of bacterial infections instead of the present seven

Cleared By India's Drug Controller, GVK Bio Expects To Complete Phase III Trials On Wyeth’s Prevnar 13 By Year End

MUMBAI - GVK Biosciences, the clinical research organization undertaking Phase III clinical trials for Wyeth's advanced version of Prevnar vaccine said it hopes to complete the studies in 12 to 13 centers by the end of the year. Wyeth is testing the vaccine in India along with many other countries to examine the new product that will fight 13 strains of bacterial infections instead of the present seven

GVK Bio Expects To Complete Phase III Trials On Wyeth’s Prevnar 13 By Year’s End

Wyeth and GVK Biosciences were cleared in May to restart the Indian trials after no links were found between the alleged death of an infant in a Bangalore-based hospital and the trials.

Related Content

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel